ASDERA develops interventions for unmet needs by utilizing a patented computational biostatistics platform to identify complex genetic risk factors in small (from n?500) epidemiological and 'failed' phase 2/3 studies.

  The ASDERA time-/pipeline:

  • Validation: Confirmation of known drug targets in epilepsy
    (2013, Pharmacogenomics)
  • Proof-of-principle: L-fucose in Crohn's disease 
    (in progress, from 2006 dbGaP data)
  • Autism: A derivative of mefenamic acid against mutism in autism (2014, Nature: Transl. Psychiatry, $500M valuation)
  • Lysosome function treatments: Intestinally absorbed derivatives of HP-a-cyclodextrin  (pat. pending) against progression of
    - carcinomas (breast cancer, https://doi.org/10.1371/journal.pone.0199012
    )
  • - neurodegeneration (Alzheimer's, Parkinson's, Huntington's, ALS)
  • - lysosomal storage diseases (NPC, TS, Fabry, Sandhoff, Farber, ...)
  • Nutritional products: Novel formulation of a-cyclodextrin (pat. granted) for use in dietary supplements and food as
    - 'fasting mimetic' to improve the natural process of aging
  • - 'adaptive vaccination' to reduce severity of initial infection with
       SARS-CoV-2 while developing COVID-19 immunity.